Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

Trial StartIcovamenibSemaglutidePositive

AI Analysis

Summary

Biomea Fusion initiated the OPAL study evaluating icovamenib in combination with low-dose semaglutide for obesity, with the first patient dosed. The study will assess effects on physical function, body weight, body composition, muscle health, and metabolic outcomes.

Clinical Trial Data

Outcome Details

First patient dosed in OPAL study

Importance:5/10

Sentiment:

0.40

obesitycombination_therapyclinical_trialicovamenibsemaglutide

Related Companies

$IBO $HIT $TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on August 13, 2026 11:00 AM

Read Original